Company intelligence / Profile preview

Fushan Silver

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Fushan Silver is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation antibody-drug conjugates (ADCs) for oncology. The company leverages a proprietary linker-payload technology platform designed to enhance the stability and therapeutic index of its candidates. Its lead programs target well-validated cancer antigens such as TROP2 and HER2, with several assets currently undergoing clinical evaluation in patients with advanced solid tumors. Fushan Silver aims to address unmet medical needs in the treatment of refractory cancers through precision medicine and innovative drug delivery systems.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibodySmall molecule
Industry: Biotech

Partnerships

Fosun Pharma

Beyond the preview

Go deeper on Fushan Silver.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fushan Silver.

Explore the full profile